Table 4.
Differential adverse event rates among prostaglandin analogs as reported in multi-center, randomized control trials summarized in Table 2
| First author/year | N |
Reported rates of adverse events |
|
|---|---|---|---|
| Ocular | Systemic | ||
| Parrish85/2003 | 410 | CH: Bim 68.6%, Trav 58.0%, Lat 47.1%, P = 0.001 Bim vs Lat Moderate CH: Bim 15.3%, Trav 10.1%, Lat 5.9% Eye irritation: Bim 10.9%, Trav 4.3%, Lat 6.6% Eyelash growth: Bim 2.9%, Trav 0.7%, Lat 0% Skin discoloration: Bim 2.9%, Trav 2.9%, Lat 1.5% |
Bim 18.2%, Trav 16.7%, Lat 16.9%. Events reported >2% were nasopharyngitis, upper respiratory tract infection, headache |
| DuBiner63/2001 | 43 | CH: Bim 14.3%, Lat 14.3% | |
| Gandolfi64/2001 | 232 | CH: Bim 36.1%, Lat 14.2%, P ≤ 0.001. Mild Eyelash growth: Bim 12.6%, Lat 4.4%, P =0.026 Ant uveitis: 1 subject each No CME or iris change |
Headache: 4.4% Lat vs 0% Bim, P = 0.026 |
| Noecker86/2003 | 269 | CH (slit-lamp): Bim 55.4%, Lat 42.5%, P <0.001 Eyelash growth: Bim > Lat, P = 0.064 Iris change: 1 subject Bim Ant uveitis: 1 subject Lat No CME |
12 serious adverse events. None reported to be related to study medication |
| Walters78/2004 | 76 | CH: Bim 39.5%, Lat 15.8%, P =0.021. Mild 14/15 cases Eye pruritis: Bim 13.2%, Lat 2.6%, P =0.20 Ant uveitis: 1 subject Lat No CME |
– |
| Netland68/2001 | 390 | CH: Trav 38.0%, Lat 27.6%, mainly mild Eyelash growth: Trav 57.1%, Lat 25.8% Iris change: Trav 3.1%, lat 5.2% No anterior uveitis, No CME |
– |
| Cantor87/2006 | 157 | CH: Bim 21.1%, Trav 14.8%, P =0.326 Ocular itching: Bim 2.3%, Trav 7.4%, P = 0.278 Iris change: 1 subject Bim |
– |
Abbreviations: Ant, anterior; Bim, bimatoprost 0.03%; CH, conjunctival hyperemia; CME, cystoid macular edema; Lat, latanoprost 0.005%; Trav, travoprost 0.004%.